Phathom Pharmaceuticals, Inc.
Securities Investigation
Investors who purchased or acquired PHAT securities are encouraged to come forward.
Investigation opened July 30, 2026
Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Phathom Pharmaceuticals, Inc. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Phathom Pharmaceuticals, Inc. (PHAT) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phathom Pharmaceuticals, Inc. (“Phathom” or “the Company”) (NASDAQ: PHAT). Investors who purchased Phathom securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Phathom has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
- 1Whether Phathom Pharmaceuticals, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- 2Whether Phathom Pharmaceuticals, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- 3Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
Key Dates
An investigation is not a lawsuit. If a complaint is filed, a lead plaintiff deadline will be set and posted here.
Why Did PHAT Stock Drop?
Phathom announced second quarter 2026 financial results and lowered its full-year 2026 net revenue guidance to $300 million to $325 million, down from the $320 million to $345 million range that the Company had reaffirmed on its February 26, 2026 fourth quarter 2025 earnings call and again on its April 30, 2026 first quarter 2026 earnings call. On the February 26 call, President and Chief Executive Officer Steve Basta stated, “Our $320 million to $345 million revenue guidance for 2026 reflects our operating expectation of continued solid growth from our GI-focused strategy.” On the April 30 call, Chief Financial Officer Sanjeev Narula told investors, “We continue to anticipate 2026 net revenue between $320 million to $345 million,” while Mr. Basta added, “We are thus maintaining our revenue guidance for the year.” During that same call, Mr. Basta also stated, “We have more than 290 reps in place to start Q2,” and Mr. Narula represented that the Company’s gross-to-net discount was tracking at the lower end of its expected range. Following this news, Phathom stock price dropped.
How Is Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) Stock Trading Today?
What Happens After You Contact Us?
Tell us about your purchase
Takes about a minute. Share count and statements are optional.
We review your transactions
Our team reviews your trades at no cost or obligation.
We keep you updated
If a case is filed, we'll contact you about your options and any deadlines.
Submitting information does not create an attorney-client relationship. Our firm works on a contingency fee basis, and you do not need to have sold your shares to contact us.
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."
Frequently Asked Questions
Has a lawsuit been filed against Phathom Pharmaceuticals, Inc.?
No complaint has been filed. BG&G is investigating whether investors may have claims. If a securities class action is filed, this page will be updated with the court, class period, and lead plaintiff deadline.
What does a securities investigation mean?
The firm is reviewing public disclosures, stock price movements, and other information to determine whether a company or its officers may have violated the federal securities laws. An investigation does not mean wrongdoing has been established.
Why should I contact the firm now?
Sharing your information early lets us review your transactions and notify you promptly if a case is filed, including any deadline to seek appointment as lead plaintiff.
Does it cost anything?
No. Our firm works on a contingency fee basis, and there is no cost or obligation to contact us.
I sold my PHAT shares. Can I still contact you?
Yes. Potential claims generally depend on when you purchased and whether you suffered a loss, not on whether you still hold the shares.
What documents should I have ready?
Brokerage statements or trade confirmations showing your PHAT purchases, sales, and holdings, including dates, share counts, and prices.